One project at a time, we're changing the way University faculty view their work—at the same time, we're realizing Wallace Coulter’s goal of “science serving humanity.”
The UVA-Coulter Translational Research Partnership awards $700,000 each year to biomedical engineering faculty members and research collaborators from the School of Medicine, the School of Engineering and other areas of the University. Together, teams of co-investigators work to develop new technologies that address unmet clinical needs, improve health care and lead to commercially available products.
In the process of funding scores of projects over the last decade, UVA-Coulter has stimulated a culture of translational research at the University,
The mission of the UVA-Coulter Translational Partnership is to support research projects that are explicitly translational in nature and in the doing so, develop and validate models of translational that can be widely adopted.
The Wallace H. Coulter Foundation announces that the University of Virginia is one of 10 universities that will form the first phase of the Coulter Translational Partnership program. The foundation provides UVA $5.9 million duiring this five year period.
The University of Virginia teams with the Coulter Foundation to create a $20 million endowment to foster collaboration between biomedical engineers and clinicians leading to new technologies to improve patient care and human health.
UVA-Coulter start-up HemoShear enters into an agreement with Takeda Pharmaceutical Company that could be worth as much as $470 million. The two companies will use HemoShear’s proprietary disease modeling platform to discover and develop novel therapeutics for liver diseases.
David Chen began his career at ImClone Systems, where he worked closely with both European regulatory agencies as well as the FDA. He holds a Master of Science in Cell and Developmental Biology from Rutgers University/Robert Wood Johnson Medical School and an MBA from UVA’s Darden School of Business. Email David Chen.
Frederick Epstein develops magnetic resonance imaging (MRI) techniques for assessing the structure, function and perfusion of the cardiovascular system, particularly in the setting of cardiovascular disease, diabetes and musculoskeletal disease. Email Fred Epstein.
Hannah Moore coordinates board meetings and facilitates approvals and permissions that faculty members need to receive funding and launch their projects. She has a background in endocrinology, rheumatology and primary care. Email Hannah Moore.
Our University Partners
These on-Grounds partners are helping to ensure that promising technologies developed by its faculty enter the marketplace, where they can benefit citizens of the Commonwealth, the nation and the world.
The LVG reviews proposals for the UVA-Coulter Oversight Committee and provides input to Coulter researchers as well as connections to industry partners who can help shape the development of their intellectual property.